Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis
Condition: Extra Pulmonary Sarcoidosis Interventions: Drug: Hydroxychloroquine; Drug: Placebo Sponsor: Hospices Civils de Lyon Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 3, 2023 Category: Research Source Type: clinical trials
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma Interventions: Drug: Hydroxychloroquine; Drug: Lipiodol; Drug: Placebo Sponsor: VA Office of Research and Development Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 3, 2023 Category: Research Source Type: clinical trials
The HAVEN study —hydroxychloroquine in ANCA vasculitis evaluation—a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan
DiscussionThis trial aims to explore Hydroxychloroquine as a treatment for patients with AAV. If effective, the need for immunosuppressive treatments such as prednisolone could be reduced. Hydroxychloroquine is safer, cheaper and has fewer adverse effects than conventional immunosuppressive treatments. This could improve patient outcomes while saving money for the NHS.Trial registrationISRCTN: ISRCTN79334891. Registered 07 June 2021.EudraCT: 2018-001268-40. Registered 13 September 2019.Clinicaltrials.gov: NCT04316494. Registered 20 March 2020. (Source: Trials)
Source: Trials - April 6, 2023 Category: Research Source Type: clinical trials
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Condition: Systemic Lupus Erythematosus Interventions: Drug: Hydroxychloroquine; Drug: Placebo Sponsors: NYU Langone Health; National Institutes of Health (NIH) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Hydroxychloroquine in Colchicine-RESistant Glucocorticoid-DependenT IdiOpathic REcurrent Pericarditis: A Randomized Clinical Trial
Condition: Pericarditis Idiopathic Recurrent Interventions: Drug: Hydroxychloroquine; Drug: Colchicine Sponsor: Hippocration General Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2023 Category: Research Source Type: clinical trials
Hydroxychloroquine in Colchicine-Resistant Glucocorticoid-Dependent Idiopathic Recurrent Pericarditis
Condition: Pericarditis Idiopathic Recurrent Interventions: Drug: Hydroxychloroquine; Drug: Colchicine Sponsor: Hippocration General Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2023 Category: Research Source Type: clinical trials
